# Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing

> **NCT00324376** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 24 (—)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Sevelamer hydrochloride

## Key facts

- **NCT ID:** NCT00324376
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2004-05
- **Target enrollment:** 24 (—)
- **Last updated:** 2015-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00324376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00324376, "Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00324376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*